scholarly journals Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials

2015 ◽  
Vol 1 (4) ◽  
Author(s):  
Sylvain Lachance ◽  
Om Dhingra ◽  
James Bernstein ◽  
Stéphanie Gagnon ◽  
Caroline Savard ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Replacement Therapy ◽  
Testosterone Undecanoate ◽  
Androgen Replacement Therapy

TESTOSTERONE UNDECANOATE: A NEW ORALLY ACTIVE ANDROGEN

1975 ◽  
Vol 80 (1) ◽  
pp. 179-187 ◽  
Author(s):  
C. Hirschhäuser ◽  
C. R. N. Hopkinson ◽  
G. Sturm ◽  
A. Coert
Keyword(s):  
Gas Chromatography ◽  
Oral Administration ◽  
Replacement Therapy ◽  
Elevated Plasma ◽  
Testosterone Undecanoate ◽  
Androgen Replacement Therapy ◽  
Normal Men ◽  
Orally Active ◽  
Elevate Plasma ◽  
Androgen Levels

ABSTRACT Oral testosterone undecanoate (TU) in arachis oil has been evaluated with a view to its possible use as a means of androgen replacement therapy. A single 100 mg dose was found to elevate plasma androgen levels and urinary 17-ketosteroid excretion in 6 normal men. Ninety mg/day and 60 mg/day doses taken by a hypogonadal man resulted in sustained levels of androgen which appeared physiological when measured by radioimmunoassay without chromatography. However, upon separation of the steroids by chromatography it was found that much of the androgen present was in fact dihydrotestosterone not testosterone. Both TU and dihydrotestosterone undecanoate were detected in plasma by gas chromatography and it is suggested that the ester is absorbed as such from the intestine and the unesterified steroid subsequently released by hydrolysis. The convenience of oral administration, the resulting prolonged elevated plasma androgen levels and the probable lack of deleterious effects on the liver may render oral TU of value where androgen replacement therapy is indicated.

scholarly journals Effect of Late Androgen Replacement Therapy on Erectile Function Through Structural Changes in Castrated Rats

2021 ◽  
Vol 9 (4) ◽  
pp. 100348
Author(s):  
Tomoya Kataoka ◽  
Yuji Hotta ◽  
Yuka Yamamoto ◽  
Ayako Fukamoto ◽  
Madoka Takeuchi ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Erectile Function ◽  
Structural Changes ◽  
Androgen Replacement Therapy

A Different View of Surfactant Development

PEDIATRICS ◽  
1992 ◽  
Vol 89 (1) ◽  
pp. 173-174
Author(s):  
RODERIC H. PHIBBS
Keyword(s):  
Clinical Trials ◽  
Replacement Therapy ◽  
Hyaline Membrane Disease ◽  
Hyaline Membrane

In Reply.— Dr Kattwinkel suggests in his letter that there has been no serious effort by investigators in neonatology and pulmonary biology to identify the best possible surfactant for use for replacement therapy in hyaline membrane disease. Furthermore, he implies that there has been a national or perhaps international conspiracy to ignore natural human surfactant in the large clinical trials done to date. In reaching these opinions, Dr Kattwinkel seems to have ignored several facts of which he should be aware.

Androgen Replacement Therapy in Hypogonadal Men

2004 ◽  
pp. 353-369
Author(s):  
Christina Wang ◽  
Ronald S. Swerdloff
Keyword(s):  
Replacement Therapy ◽  
Androgen Replacement Therapy

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

Sign in / Sign up

Export Citation Format

Share Document